ENSG vs GEL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ENSG and GEL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ENSG and GEL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

The Ensign Group runs a network of independently operated skilled nursing facilities, senior living communities, and rehabilitation services across the United States, plus a growing real estate arm (Standard Bearer). As of mid-2026 its subsidiaries operated roughly 398 healthcare operations, including about 48 senior living communities, across 17 states, with a real estate portfolio of roughly 183 properties. The business model is to acquire underperforming but strategically located facilities and turn them into profitable local operations, generating revenue mostly from Medicare, Medicaid, and private-insurance reimbursement for short-term rehab and long-term care.

Full ENSG guide

Genesis Energy, L.P. (NYSE: GEL) is a diversified midstream energy master limited partnership headquartered in Houston. As an MLP, it is a pass-through entity: investors own limited-partnership units rather than corporate stock, and each year the partnership sends unitholders a Schedule K-1 reporting their share of income, gains, losses, and deductions, instead of the 1099 a normal stock generates. Genesis pays a quarterly cash distribution (declared at $0.18 per common unit, or $0.72 annualized, for the quarter ended March 31, 2026, after a raise) that is central to the investment case, and it also has higher-cost preferred units it has been redeeming to lower its cost of capital.

Full GEL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ENSG drivers: Serial-acquisition growth engine; Occupancy and skilled-mix gains.
• GEL drivers: Offshore Gulf of Mexico volume growth; Shenandoah tie-in and multi-year offshore pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Ensign derives the majority of its revenue from Medicare and Medicaid, so any cut, freeze, or unfavorable change to government reimbursement rates would pressure margins directly. For GEL, gEL carries commodity and volume exposure: while much of its revenue is fee-based, offshore throughput ultimately depends on producers drilling and completing deepwater wells, and marine and sulfur results move with refinery activity and shipping demand.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ENSG if you believe its drivers more; GEL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ENSG and GEL guides.

ENSG. Ensign trades at a premium to typical healthcare-facility peers, reflecting its consistent double-digit growth and strong balance sheet (roughly $540 million cash against about $143 million of debt in early 2026). Q1 2026 revenue grew about 18% year over year to roughly $1.39 billion with adjusted EPS up more than 20%, and management raised full-year guidance. The premium multiple assumes the acquisition-led growth continues.

GEL. All figures are hedged and approximate and should be verified against Genesis Energy's latest filings and a live quote. MLPs like GEL are typically valued on distributable cash flow, distribution coverage, and yield rather than simple earnings multiples, and the Schedule K-1 tax reporting materially affects after-tax outcomes. Nothing here is investment advice.

Headline figures (approximate, July 2026): ENSG shows revenue (ttm) ~$5.3B, 2026 revenue guidance ~$5.81B to $5.86B, 2026 eps guidance (diluted) ~$7.48 to $7.62, market cap ~$9.9B; GEL shows distribution / yield Quarterly common-unit distribution declared at $0.18 ($0.72 annualized) for Q1 2026, after a raise; preferred units paid separately. Yield depends on the live unit price, so calculate it yourself., adjusted ebitda direction Management has guided to meaningful adjusted EBITDA growth in 2026 (mid-to-high teens percentage range communicated), driven by ramping offshore volumes. Directional guidance only; confirm actual results and any revisions., leverage Ended Q1 2026 with roughly $3.22 billion of long-term debt plus preferred units; management is actively deleveraging and redeeming higher-cost preferreds. Treat as a work in progress, not a fixed figure., segments Three focused segments after the soda ash exit: offshore pipeline transportation (largest margin contributor), marine transportation, and onshore transportation & services including sulfur / refinery services..

ENSG and GEL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ENSG and GEL exposure against your real portfolio. It is not an investment adviser.